# Novartis to build $92M cell and gene therapy plant in Stein, Switzerland

Novartis announced plans to construct a new cell and gene therapy production facility in Stein, Switzerland, with phased investments of approximately CHF 90 million ($92 million). The plant will support CAR-T drug Kymriah and create up to 450 jobs.

- Type: New facility
- Announced: 2018-08-28
- Where: Stein, Switzerland
- Value: $92.0M
- Jobs: 450
- Status: announced
- Products: cell and gene therapies, CAR-T drug Kymriah
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Novartis](https://endata.com/companies/32041.md)

## Sources

- [bioprocessintl.com](https://www.bioprocessintl.com/bioprocess-insider/novartis-constructing-92m-car-t-plant-as-kymriah-arrives-in-eu), 2018-08-28: "Phased investments totalling approximately CHF 90 million [US$92 million] will be made over the next few years to support the new facility."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.